JP2013535963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535963A5 JP2013535963A5 JP2013519215A JP2013519215A JP2013535963A5 JP 2013535963 A5 JP2013535963 A5 JP 2013535963A5 JP 2013519215 A JP2013519215 A JP 2013519215A JP 2013519215 A JP2013519215 A JP 2013519215A JP 2013535963 A5 JP2013535963 A5 JP 2013535963A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- diabetes
- isolated
- complex
- high affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 230000000599 auto-anti-genic effect Effects 0.000 claims 23
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 15
- 102000043131 MHC class II family Human genes 0.000 claims 14
- 108091054438 MHC class II family Proteins 0.000 claims 14
- 206010012601 diabetes mellitus Diseases 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 claims 4
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims 4
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims 2
- 102000010792 Chromogranin A Human genes 0.000 claims 2
- 108010038447 Chromogranin A Proteins 0.000 claims 2
- 101710172364 Glucose-6-phosphatase 2 Proteins 0.000 claims 2
- 101000930907 Homo sapiens Glucose-6-phosphatase 2 Proteins 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 claims 1
- 108010058432 Chaperonin 60 Proteins 0.000 claims 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 claims 1
- 101000738765 Homo sapiens Receptor-type tyrosine-protein phosphatase N2 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010076181 Proinsulin Proteins 0.000 claims 1
- 102100037404 Receptor-type tyrosine-protein phosphatase N2 Human genes 0.000 claims 1
- 102000004248 Zinc Transporter 8 Human genes 0.000 claims 1
- 108090000702 Zinc Transporter 8 Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 206010022498 insulinoma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010066381 preproinsulin Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36443710P | 2010-07-15 | 2010-07-15 | |
| US61/364,437 | 2010-07-15 | ||
| PCT/IL2011/000563 WO2012007950A2 (en) | 2010-07-15 | 2011-07-14 | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013535963A JP2013535963A (ja) | 2013-09-19 |
| JP2013535963A5 true JP2013535963A5 (enExample) | 2014-08-28 |
Family
ID=44504047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519215A Pending JP2013535963A (ja) | 2010-07-15 | 2011-07-14 | Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130189284A1 (enExample) |
| EP (1) | EP2593480A2 (enExample) |
| JP (1) | JP2013535963A (enExample) |
| CA (1) | CA2805478A1 (enExample) |
| WO (1) | WO2012007950A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9695410B2 (en) | 2010-07-15 | 2017-07-04 | Technion Research & Development Foundation Limited | Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides |
| RU2727573C2 (ru) * | 2014-09-26 | 2020-07-22 | Ти Юниверсити Оф Бритиш Коламбиа | Комбинация кинуренина и антигенпредставляющие клетки (apc) в качестве терапевтических средств и способ их применения в иммуномодуляции |
| EP3221344A2 (en) * | 2014-11-21 | 2017-09-27 | Immusant Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
| GB201506112D0 (en) * | 2015-04-10 | 2015-05-27 | Midatech Ltd And Inst Nationale De La Sant� Et De Al Rech Medicale And University College Car | Nanoparticle-based antigen specific immunotherapy |
| US20190031759A1 (en) | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
| US11179448B2 (en) | 2015-07-16 | 2021-11-23 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory T cells and use of same in immunotherapy |
| GB201520603D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| IL268126B2 (en) | 2017-01-18 | 2024-02-01 | Yeda Res & Dev | Genetically engineered Veto cells and their uses in immunotherapy |
| US12153056B2 (en) | 2019-07-15 | 2024-11-26 | Washington University | Compositions for and methods of diagnosing, prognosing, and treating diabetes |
| EP4384603A1 (en) | 2021-08-10 | 2024-06-19 | Gamida-Cell Ltd. | Engineered nk cells, methods of their production and uses thereof |
| GB202210967D0 (en) * | 2022-07-27 | 2022-09-07 | Univ Birmingham | Tolerogenic peptides i |
| AU2023314797A1 (en) * | 2022-07-29 | 2024-12-12 | Repertoire Immune Medicines, Inc. | T cell epitopes associated with type 1 diabetes |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| DE19525784A1 (de) | 1995-07-14 | 1997-01-16 | Boehringer Mannheim Gmbh | Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD) |
| WO1997010847A1 (en) * | 1995-09-21 | 1997-03-27 | University Of Utah Research Foundation | Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells |
| US6037137A (en) | 1997-02-20 | 2000-03-14 | Oncoimmunin, Inc. | Fluorogenic peptides for the detection of protease activity |
| AU741130B2 (en) * | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| EP1274852A2 (en) | 2000-04-12 | 2003-01-15 | University Of Rochester | Targeted vaccine delivery systems |
| CN1305906C (zh) * | 2000-08-14 | 2007-03-21 | 欧加农股份有限公司 | 特异性mhc－肽复合物的抗体的诊断用途 |
| US8314210B2 (en) * | 2002-07-12 | 2012-11-20 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the generation of MHC class II compounds by peptide exchange |
| NZ552667A (en) * | 2004-07-23 | 2009-04-30 | Inst Medical W & E Hall | Therapeutic and diagnostic agents |
| EP1877440A4 (en) * | 2005-03-18 | 2009-07-29 | Univ Oregon Health & Science | RECOMBINANT MHC MOLECULES SUITABLE FOR MANIPULATING ANTIGEN-SPECIFIC T CELLS |
| DK2131856T3 (da) | 2007-03-07 | 2014-12-15 | Uti Limited Partnership | Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande |
-
2011
- 2011-07-14 EP EP11746669.8A patent/EP2593480A2/en not_active Withdrawn
- 2011-07-14 WO PCT/IL2011/000563 patent/WO2012007950A2/en not_active Ceased
- 2011-07-14 US US13/810,248 patent/US20130189284A1/en not_active Abandoned
- 2011-07-14 CA CA2805478A patent/CA2805478A1/en not_active Abandoned
- 2011-07-14 JP JP2013519215A patent/JP2013535963A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535963A5 (enExample) | ||
| JP2013538555A5 (enExample) | ||
| CA2861793C (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| CA2856141C (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| JP2012143232A5 (enExample) | ||
| JP2018527884A5 (enExample) | ||
| RU2013107776A (ru) | Антитело к противоопухолевому антигену и способы применения | |
| RU2015141418A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| JP2021107397A (ja) | 抗ｉｌ２３抗体を使用してクローン病を治療するための方法 | |
| CA2792740A1 (en) | Antibodies with ph dependent antigen binding | |
| RU2018102526A (ru) | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение | |
| JP2019515646A (ja) | Ｐｄ−ｌ１に対する結合メンバー | |
| JP2010511388A5 (enExample) | ||
| JP2018166506A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| US10131709B2 (en) | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 | |
| JP2012518425A5 (enExample) | ||
| JP2012531212A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2018502060A5 (enExample) | ||
| RU2017134140A (ru) | Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования | |
| HRP20220553T1 (hr) | Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela | |
| JP2012501670A5 (enExample) | ||
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| JP2009533021A5 (enExample) |